financetom
Business
financetom
/
Business
/
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
Oct 29, 2025 10:02 AM

12:34 PM EDT, 10/29/2025 (MT Newswires) -- American Tower's ( AMT ) solid Q3 results and slightly higher full-year guidance were "overshadowed" by a legal dispute with Echostar ( SATS ) over tower payments, but the market's reaction is "overdone" given the wireless infrastructure provider's minimal 2% revenue exposure to Echostar ( SATS ) and the stock's attractive valuation, UBS Securities said in a note emailed Wednesday.

American Tower ( AMT ) sued EchoStar ( SATS ) unit Dish Wireless after Dish sent a letter stating it was no longer obligated to pay future tower payments, Bloomberg reported Wednesday, citing a lawsuit filed last week.

The nonpayment had already been weighing on American Tower ( AMT ) shares, UBS said. Assuming EchoStar's ( SATS ) complete removal from estimates, UBS said American Tower's ( AMT ) shares would trade at 17 times and 16 times 2026 and 2027 estimated adjusted funds from operations, respectively, well below the company's 10-year average multiple of 21 times.

American Tower's ( AMT ) services momentum remains strong, with US application volumes up 20% and colocation applications up 40% as carriers expand networks, while 2025 leasing is projected at $161 million with churn near 1%. Data center revenue grew 14% year over year, driven by hybrid-cloud and artificial intelligence demand, with further growth of 15% expected in Q4 and 14% in 2026, UBS said.

UBS reiterated a buy rating and a $260 price target, calling the pullback an "attractive opportunity," according to the report.

Price: 182.48, Change: -0.24, Percent Change: -0.13

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Airbus beats Q3 expectations but cuts A220 production target
Airbus beats Q3 expectations but cuts A220 production target
Oct 29, 2025
PARIS (Reuters) -Europe's Airbus on Wednesday reported higher than expected third-quarter profits and revenues led by commercial jetliner deliveries and robust gains in helicopters and defence. It reaffirmed its main financial and delivery targets but cut the production goal for its smallest model and now aims to assemble 12 of the Canadian-designed A220s a month in 2026, down from a...
Starr Announces Acquisition of IQUW Group
Starr Announces Acquisition of IQUW Group
Oct 29, 2025
Starr set to become ninth-largest Lloyd’s agency NEW YORK & LONDON--(BUSINESS WIRE)-- Starr, a global investment and insurance organization, today announced that it has entered into a definitive agreement to acquire IQUW Group. The acquisition of IQUW Group will expand the classes of business that Starr underwrites and will position the combined company for growth across a broader range...
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
Oct 29, 2025
12:34 PM EDT, 10/29/2025 (MT Newswires) -- American Tower's ( AMT ) solid Q3 results and slightly higher full-year guidance were overshadowed by a legal dispute with Echostar ( SATS ) over tower payments, but the market's reaction is overdone given the wireless infrastructure provider's minimal 2% revenue exposure to Echostar ( SATS ) and the stock's attractive valuation, UBS...
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Oct 29, 2025
12:32 PM EDT, 10/29/2025 (MT Newswires) -- Vor Biopharma ( VOR ) said Wednesday that its partner RemeGen presented 48-week data from a phase 3 study in China showing that telitacicept delivered consistent quality-of-life improvement in patients with generalized myasthenia gravis. All patients treated with telitacicept for 48 weeks achieved an at least two-point improvement in Myasthenia Gravis Activities of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved